Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;14(6):458-64.
doi: 10.1007/s12094-012-0824-0.

Trends in prostate cancer survival in Spain: results from population-based cancer registries

Affiliations

Trends in prostate cancer survival in Spain: results from population-based cancer registries

Rafael Marcos-Gragera et al. Clin Transl Oncol. 2012 Jun.

Abstract

Introduction: The aim of this study is to analyse the evolution of the survival of patients diagnosed with prostate cancer during the period 1995-2003.

Material and methods: This is a population survival study of incident cases of prostate cancer in four Spanish areas: Basque Country, Girona, Murcia and Navarra. We calculated the relative survival (RS) at 5 years and its 95% confidence intervals using a cohort analysis and adjusted for age. To assess the trend in survival between the periods (1995-1999 and 2000-2003) a Poisson regression model was used, adjusting for age, region and period, obtaining the relative risk of death.

Results: The number of patients diagnosed during the 1995- 1999 period was 6493 and 8331 in the period 2000-03. The RS at 5 years adjusted for age increased significantly, from 75.3% (95% CI 73.3-77.2) in the period 1995-99 to 85% (95% CI 83.4-86.4) in the period 2000-03.

Conclusion: In Spain the survival of patients with prostate cancer has increased significantly from 1999 to 2003, probably due to the advancement in diagnosis produced by the opportunistic screening of prostate-specific antigen (PSA). Differences in the dissemination and use of the PSA level could explain the observed geographic differences in the increase of survival. It would be necessary to carry out studies to quantify the produced overdiagnosis by screening with PSA in prostate cancer.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Med Clin (Barc). 2008 Oct;131 Suppl 1:19-24 - PubMed
    1. Actas Urol Esp. 2008 Feb;32(2):184-9 - PubMed
    1. Prog Urol. 2008 Jan;18(1):53-9 - PubMed
    1. Lancet Oncol. 2010 Aug;11(8):725-32 - PubMed
    1. J Natl Cancer Inst. 2009 Mar 18;101(6):374-83 - PubMed

LinkOut - more resources